Dapagliflozin Range Advisory Board

Date: 15thDec 2022

Venue: Marriott Elzamalek Hotel, Cairo (TBC)
Moderators: Sanofi Medical Team

Advisory Board Key objectives:

o To identify Patients’ unmet needs & gaps in management of T2DM

o To be familiar with current treatment strategies, timing, treatment dosing & the
appropriate sequencing of different OADs in T2DM management.

o To get advisors’ reflections on new ADA/EASD 2022 guidelines regarding

positioning of SGLT2i/competitors (DDP4-i) with respect to holistic/personalized
approaches in different patients’ groups.
o To gather insights about Dapagliflozin &Dapagliflozin –Metformin 10/1000
combination use in clinical practice and different patient profiles eligible for these
formulations.

o To gain insights on dapagliflozin latest clinical studies (Dapa-HF/DELIVER/DAPA-

CKD) & Dapagliflozin/Metformin studies considering different profiles within the
diabetic patients and beyond.

o To better understand KOLs behaviours toward planned new combinations

(Dapagliflozin/Metformin- 5/1000 & Dapagliflozin/Saxaglibtin) to be launched by
Sanofi, and identify eligible patients’ profiles

o To obtain advisors recommendations for HCPs education and opportunities toward

increasing patients’ awareness on diabetes and its management including new
digital initiatives and multidisciplinary approaches.
 Advisory Board Members:

1.Prof. Nabil El Kafrawy Professor of Diabetology & Endocrinology, Menoufia

University
2.Prof. Khalifa Abdallah Professor of Diabetology & Endocrinology, Alexandria
University
3.Prof. Yehia Ghanem Professor of Diabetology & Endocrinology, Alexandria
University
4.Prof. Hesham El Gayar Professor of Diabetology & Endocrinology, Ain Shams
University
5.Prof. Ibrahem El Ebrashy Professor of Diabetology & Endocrinology, Cairo
University
6. Prof. Nermin Shereeba Professor of Diabetology & Endocrinology, Ain Shams
University
7.Prof. Mary Nabil Professor of Diabetology & Endocrinology, Cairo
University
8.Prof. Ehab Salem Professor of Diabetology & Endocrinology, Zagazig
University
9.Prof.Asem Seif Professor of Diabetology & Endocrinology, Cairo
University
10.Samir Helmy Asaad Professor of Diabetology & Endocrinology, Alexandria
University
 Time
Topic for Discussion Contributors Duration
From To

Dr. Mawell Sameh

Foundation
 Opening & Welcoming Medical Lead, 5 min 05:00 05:15
Egypt & Sudan

 Patients’ unmet needs & gaps in

management of T2DM
Dr. Heba Elsedfy &
 Current positioning of different OADs 45 mins 05:15 PM 06:00 PM
All Advisors
within treatment landscape of T2DM in
clinical practice

 Reflections on new EASD 2022

guidelines regarding positioning of
SGLT2i/competitors (DDP4-i) with
respect to holistic/personalized
60
approaches in different patients’ Dr. Heba Elsedfy & 06:00 PM 07:00 PM
mins
groups All Advisors

 Insights on dapagliflozin latest clinical

studies (Dapa HF/DELIVER/DAPA CKD)
& Dapagliflozin/Metformin studies

ALL 30
 Break 07:00 PM 07:30 PM
mins

Heba Elsedfy 15
 Diabetes Market Overview 07:30 PM 07:45 PM
mins

 Opportunity for new combinations in

T2DM management (Dapagliflozin\ Dr. Heba Elsedfy &
Saxaglibtin combination- 60
All Advisors 07:45 PM 08:45 PM
Dapagliflozin/Metformin 5/1000 mg), mins
and identify eligible patient profiles
per each

45 08:45 PM 09:30 PM
 Advisors’ recommendations
 regarding:
o Optimizing multidisciplinary
approaches in management of Dr. Heba Elsedfy &
patients with type II diabetes. All Advisors
mins
o HCPs educational needs
considering digital initiatives.
o Patients’ awareness needs and
activation in respect to
cardiometabolic TA.

Note: preparatory calls with advisors and preread will be provided to members in advance to the
advisory board